Loading company…
Oslo-based biotech developing TCR-NK cell therapies for solid tumors, built on its proprietary platform.
Zelluna Immunotherapy AS develops cell therapies for solid cancers using its proprietary TCR-NK platform, which uses T cell receptors to enhance natural killer cell activity. Founded in 2016 and headquartered in Oslo, Norway, by Anders Tuv and Hans Robinson, the company is led by CEO Namir Hassan. In November 2025 it raised NOK 55 million in a private placement of 5.5 million shares at NOK 10, with 315,639 more shares allocated through a retail offering.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in